Flugen Inc.
Madison, WI
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 597 Science Dr, Madison, WI 53711, USA
- Website
- flugen.com
- Founded
- 2007
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $741,722 |
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Tendel Therapies Inc. | Kensington, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Osivax | Lyon, Auvergne-Rhône-Alpes | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Solaris Vaccines, Inc. | Fort Collins, CO | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Inhalon Biopharma, Inc. | Morrisville, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Medigen, Inc. | Frederick, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Flugen Inc. is a biopharmaceutical company based in Madison, Wisconsin, specializing in the development of innovative intranasal influenza vaccine technologies. As a for-profit organization registered in SAM.gov, the company focuses on advancing vaccine research and development, with a particular emphasis on creating novel approaches to influenza prevention. The company provides specialized biomedical research services to federal agencies, primarily targeting vaccine development and medical research solutions.
The company's federal contract work is currently focused on a specific research project awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR). This $741,722.15 firm-fixed-price definitive contract, awarded on July 25, 2025, aims to identify humoral correlates of protection following H3N2 M2SR vaccination. The contract's primary objective is to support clinical development of an M2SR strategy that can induce both seasonal influenza immunity and pre-pandemic protection. The contract does not utilize any specific set-aside designation and is scheduled for completion by February 28, 2027.
Flugen Inc. has been particularly active in federal grant awards, primarily through the Defense Health Agency's Military Medical Research and Development program. The company has received multiple project grants totaling over $11.8 million, focusing on intranasal influenza vaccine research. These grants support critical research initiatives, including optimizing downstream recovery and stabilization of vaccine drug substances, developing scalable manufacturing methods, conducting toxicity testing, and investigating the safety and immunogenicity of H3N2 M2SR monovalent influenza vaccines. The grant work spans multiple years, with current projects running through March 31, 2027, and aims to advance vaccine technology that could potentially benefit military personnel and broader public health populations.
Quick answers
Is Flugen Inc. registered in SAM.gov?
Yes. Flugen Inc.'s SAM.gov registration is active through November 12, 2026.
What is Flugen Inc.'s CAGE code?
Flugen Inc.'s CAGE code is 54YS4, and its Unique Entity ID (UEI) is M9FHAR3RBML5.
How much has Flugen Inc. received in federal contracts?
Federal contracts obligated $741,722 to Flugen Inc. in fiscal year 2025.
How does Flugen Inc. rank among federal contractors?
Flugen Inc. ranked #18 in NAICS 325414 in FY2025.
What is Flugen Inc.'s most recent federal award?
Flugen Inc.'s most recent federal contract award is The overall objective of this contract is to identify humoral correlates of protection following H3N2 M2SR vaccination… (75A50125C00005), from Office of the Assistant Secretary for Preparedness and Response, on July 25, 2025.
On GovTribe
See Flugen Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors